LOG IN
SIGN UP
MARKET
HEPA
HEPA
Hepion Pharmaceuticals Inc
NASDAQ
Real-time Quotes | Nasdaq Last Sale
0.7700
+0.0499
+6.93%
Opening 13:12 05/27 EDT
OPEN
0.7274
PREV CLOSE
0.7201
HIGH
0.7999
LOW
0.7274
VOLUME
190.37K
TURNOVER
108.60K
52 WEEK HIGH
2.318
52 WEEK LOW
0.6101
MARKET CAP
58.70M
P/E (TTM)
-1.6527
1D
5D
1M
3M
1Y
5Y
CORRECTING and REPLACING - Hepion Pharmaceuticals, Inc.
EDISON, N.J., May 27, 2022 (GLOBE NEWSWIRE) -- In the press release issued earlier today by Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), we've been informed by the company that in both the headline and first paragraph the name 'Recofilstat' should be 'Renco...
GlobeNewswire · 1d ago
Hepion Pharmaceuticals Highlights Upcoming Phase 2 Clinical Trials of Recofilstat at 5th Global NASH Congress
EDISON, N.J., May 27, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohep...
GlobeNewswire · 1d ago
Hepion Pharma announces clinical collaboration with HepQuant for a phase 2b NASH trial
Hepion Pharmaceuticals (NASDAQ:HEPA) on Tuesday entered into a clinical collaboration with Denver, Colo.-based HepQuant, a privately held company with investigational technology for evaluating liver function and health in patients with
Seekingalpha · 05/03 13:54
BRIEF-Hepion Pharmaceuticals Announces Clinical Collaboration With HepQuant In Phase 2B NASH Trial
reuters.com · 05/03 12:31
Hepion Pharmaceuticals Announces Clinical Collaboration with HepQuant in Phase 2b NASH Trial
- HepQuant Evaluation Offers Sensitive Measurement of Hepatic Function and Correlation with Clinical Outcomes - - Dedicated Phase 2b Trial Supports Overarching NASH Program for Rencofilstat - - Four-Month, Three Arm Trial will Inform on Numerous NASH Funct...
GlobeNewswire · 05/03 12:00
Hepion Pharmaceuticals to Present at the Q1 Investor Summit Conference
EDISON, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatoh...
GlobeNewswire · 03/07 13:00
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2022
Upgrades
Benzinga · 02/28 15:27
--Cantor Fitzgerald Starts Hepion Pharmaceuticals at Overweight With $3.50 Price Target
MT Newswires · 02/28 07:50
No Data
Learn about the latest financial forecast of HEPA. Analyze the recent business situations of Hepion Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 2 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average HEPA stock price target is 4.750 with a high estimate of 6.00 and a low estimate of 3.500.
Current 0.7656
EPS
Actual
Estimate
-0.10-0.08-0.05-0.03
Institutional Holdings
Institutions: 48
Institutional Holdings: 7.67M
% Owned: 10.07%
Shares Outstanding: 76.23M
TypeInstitutionsShares
Increased
9
140.44K
New
5
17.14K
Decreased
11
213.92K
Sold Out
9
184.22K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
Gary Jacob
Chief Executive Officer/Chief Scientific Officer/Director
Robert Foster
Chief Financial Officer
John Cavan
Other
Eddie Cheung
Other
Todd Hobbs
Independent Director
Timothy Block
Independent Director
John Brancaccio
Independent Director
Arnold Lippa
Independent Director
Petrus Wijngaard
No Data
No Data
About HEPA
Hepion Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The Company is focused on the development of drug therapy for treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis and other liver diseases. The Company’s cyclophilin inhibitor, CRV431, offer benefits to address these multiple complex pathologies. CRV431 is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease. The Company has created an AI platform, called AI-POWR, which stands for Artificial Intelligence Precision Medicine Omics World database access and Response and clinical outcomes. The platform helps to identify which NASH patients will best respond to CRV431, potentially shortening development timelines and increasing the delta between placebo and treatment groups.
Webull offers kinds of Hepion Pharmaceuticals Inc stock information, including NASDAQ:HEPA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HEPA stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading HEPA stock methods without spending real money on the virtual paper trading platform.